Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy.

[1]  C. Coban,et al.  Induction of Plasmodium falciparum Transmission-Blocking Antibodies in Nonhuman Primates by a Combination of DNA and Protein Immunizations , 2004, Infection and Immunity.

[2]  L. Zou,et al.  Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. , 2003, Vaccine.

[3]  A. Saul,et al.  Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism. , 2001, Vaccine.

[4]  J. Sattabongkot,et al.  Development of a Method for the In Vitro Production of Plasmodium vivax Ookinetes , 2001, The Journal of parasitology.

[5]  R. Sinden,et al.  P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions , 2001, The EMBO journal.

[6]  D. Kaslow,et al.  Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate. , 2001, Experimental parasitology.

[7]  D. Kaslow,et al.  Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability of Plasmodium vivax To Infect Mosquitoes , 2000, Infection and Immunity.

[8]  D. Kaslow,et al.  A Region of Plasmodium falciparumAntigen Pfs25 That Is the Target of Highly Potent Transmission-Blocking Antibodies , 2000, Infection and Immunity.

[9]  R. Kennedy,et al.  DNA vaccination strategies against infectious diseases. , 1999, International journal for parasitology.

[10]  Nirbhay Kumar,et al.  Immunization of Mice with DNA-Based Pfs25 Elicits Potent Malaria Transmission-Blocking Antibodies , 1999, Infection and Immunity.

[11]  D. Kaslow,et al.  Sequence Polymorphism in Two Novel Plasmodium vivax Ookinete Surface Proteins, Pvs25 and Pvs28, That Are Malaria Transmission-blocking Vaccine Candidates , 1998, Molecular medicine.

[12]  G. Butcher.  Antimalarial drugs and the mosquito transmission of Plasmodium. , 1997, International journal for parasitology.

[13]  T. Tsuboi,et al.  Two antigens on zygotes and ookinetes of Plasmodium yoelii and Plasmodium berghei that are distinct targets of transmission-blocking immunity , 1997, Infection and immunity.

[14]  D. Kaslow,et al.  A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines , 1997, Infection and immunity.

[15]  P. Barr,et al.  Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum , 1994, Infection and immunity.

[16]  J. Coligan,et al.  A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains , 1988, Nature.

[17]  S. Gurunathan,et al.  DNA vaccines: immunology, application, and optimization*. , 2000, Annual review of immunology.